Developing a paradigm of drug innovation: an evaluation algorithm

Caprino, L.; Russo, Pierluigi

doi:10.1016/j.drudis.2006.09.009

Cited by 18 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As mentioned by Ekins and Arnold, the decisions suggested in such an approach could be based on one of a number of algorithms, such as a decision tree approach that has been widely used in health economic analysis [7] and drug innovation assessment algorithm analysis [8].…”

Section: Decision-analytic Approachesmentioning

confidence: 99%

Cost‐Effectiveness Analyses Throughout the Drug Development Life Cycle

Arnold

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Cost‐effectiveness analysis (CEA) is a systematic, quantitative method for summarizing health benefits and health resources of various treatment options into single numbers or ratios so that policy makers can choose among them. Computer modeling of cost‐effectiveness may play a significant role in informing the pharmaceutical decision‐making process throughout a product's life cycle, increasing the likelihood of reimbursement and broad use.

show abstract

Section: Decision-analytic Approachesmentioning

confidence: 99%

Cost‐Effectiveness Analyses Throughout the Drug Development Life Cycle

Arnold

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

show abstract

“…An Italian algorithm was developed to quantify the value of innovation, in the hope of capturing patients, policymakers and pharmaceutical companies’ perspectives in the innovation process [38]. The Innovation Assessment Algorithm (IAA) had three key aims: first, to take into account and incorporate different properties of drug innovation; second, to provide a numeric weight as a measure of the innovative value of a drug and third, to reassess innovation over time, by incorporating clinical evidence emerging post-marketing authorisation.…”

Section: Different Approaches To Valuing Pharmaceutical Innovation Inmentioning

confidence: 99%

The role of funding and policies on innovation in cancer drug development

Kanavos

Sullivan

Lewison

et al. 2010

ecancer

View full text Add to dashboard Cite

“…To this end, the Innovation Assessment Algorithm (IAA), developed and presented by Prof. Luciano Caprino and Dr Pierluigi Russo during the six-month Italian Presidency of the European Union (2003), was utilized. The Algorithm, published in Drug Discovery Today in 2006 [1], considers the innovative quality of a medicine not as a single, distinct property, but as a combination of several properties that may be represented like a decision tree. Each branch of the tree, corresponding to a property connected with innovation, is assigned a fixed numerical value.…”

Section: Purposementioning

confidence: 99%

Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm

Civalleri¹,

Licata²

2012

View full text Add to dashboard Cite

Aim: the aim of this study was to assess the innovative quality of a medicine based on agomelatine, authorized by the European Commission through a centralized procedure on 19th February 2009 and distributed in Italy under the brands Valdoxan^® and Thymanax^®.

Methodology: the degree of innovation of agomelatine was determined through the Innovation Assessment Algorithm (IAA), which considers the innovative quality of a medicine as a combination of multiple properties. The algorithm may be represented as a decision tree, with each branch corresponding to a property connected with innovation and having a fixed numerical value. The sum of these values establishes the degree of innovation of the medicine. The IAA is articulated in two phases: the first assesses the efficacy of the drug based on the clinical trials presented in support of the registration application (IAA-efficacy); the second reconsiders the degree of innovation on the basis of the efficacy and safety data resulting from clinical practice once the drug has been placed on the market (IAA-effectiveness).

Results and conclusions: the score obtained for agomelatine was 592.73 in the efficacy phase and 291.3 in the effectiveness phase. The total score for the two phases was 884, which is equivalent to a good degree of innovation for the molecule

show abstract

Developing a paradigm of drug innovation: an evaluation algorithm

Cited by 18 publications

References 15 publications

Cost‐Effectiveness Analyses Throughout the Drug Development Life Cycle

Cost‐Effectiveness Analyses Throughout the Drug Development Life Cycle

The role of funding and policies on innovation in cancer drug development

Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm

Contact Info

Product

Resources

About